Table 1.
Sample baseline sociodemographic and medical characteristics (n = 88)
| Total(n = 88) | REACH (n = 43) | Education (n = 45) | Between Group | ||
|---|---|---|---|---|---|
| t or χ 2 | p value | ||||
| Sociodemographic characteristics | |||||
| Female | 100.00% (88/88) | 100.00% (43/43) | 100.00% (45/45) | ||
| Age (in years, Range: 31–81) | M = 58.34 (SD = 10.37) | M = 57.77 (SD = 11.22) | M = 58.89 (SD = 9.58) | .51 | .62 |
| Race/Ethnicity | .211 | .65 | |||
| White/Caucasian & Non-Latina | 92.05% (81/88) | 90.70% (39/43) | 93.33% (42/45) | ||
| Hispanic/Latina | 3.41% (3/88) | 4.65% (2/43) | 2.22% (1/45) | ||
| Biracial | 1.14% (1/88) | 2.33% (1/43) | 0.00% (0/45) | ||
| Native American/ Alaskan Native | 1.14% (1/88) | 2.33% (1/43) | 0.00% (0/45) | ||
| Black/African American | 0.00% (0/88) | 0.00% (0/43) | 0.00% (0/88) | ||
| Other | 2.27% (2/88) | 0.00% (0/43) | 4.44% (2/45) | ||
| Education (median) | Bachelor’s degree | Associate degree | Bachelor’s degree | 1.45 | .15 |
| Household income (median) | $71,000–$80,000 | $71,000–$80,000 | $61,000–$70,000 | –.13 | .90 |
| Married or partnered | 76.14% (67/88) | 79.07% (34/43) | 73.33% (33/45) | .40 | .53 |
| Children (1 or more) | 76.14% (67/88) | 81.40% (35/43) | 71.11% (32/45) | 1.28 | .26 |
| Cancer treatment history | |||||
| Months from end of treatment (Range 1–36) | M = 13.83 (SD = 8.54) | M = 14.42 (SD = 9.38) | M = 13.33 (SD = 7.64) | –.64 | .52 |
| % who received: | |||||
| 1)Surgery | 1) 100.00% (88/88) | 1) 100.00% (43/43) | 1) 100.00% (45/45) | ||
| 2)Chemotherapy | 2) 34.09% (30/88) | 2) 39.53% (17/43) | 2) 28.89% (13/45) | 2)1.11 | 2).29 |
| 3)Targeted Therapy | 3) 10.23% (9/88) | 3)6.98% (3/43) | 3) 13.33% (6/45) | 3).97 | 3).33 |
| 4)Radiation | 4) 68.18% (60/88) | 4) 69.77% (30/43) | 4) 66.67% (30/45) | 4).10 | 4).76 |
| 5)Ovarian Suppression | 5) 6.82% (6/88) | 5) 6.98% (3/43) | 5) 6.67% (3/45) | 5).00 | 5)1.00 |
| % BL AET Type: | |||||
| 1)Aromatase Inhibitors | 1) 62.50% (55/88) | 1) 65.12% (28/43) | 1) 60.00% (27/45) | .25 | .62 |
| 2)Tamoxifen | 2) 37.50% (33/88) | 2) 34.88% (15/43) | 2) 40.00% (18/45) | ||
| Months between initial AET Rx date & enrollment | M = 13.11 (SD = 8.29) | M = 13.74 (SD = 8.21) | M = 12.51 (SD = 8.41) | –.70 | .49 |
| Cancer stage | |||||
| 0 | 5.68% (5/88) | 6.98% (3/43) | 4.44% (2/45) | .392 | .53 |
| I | 71.59% (63/88) | 67.44% (29/43) | 75.56% (34/45) | ||
| II | 18.18% (16/88) | 25.58% (11/43) | 11.11% (5/45) | ||
| III | 4.55% (4/88) | 0.00% (0/43) | 8.88% (4/45) |
Note: BL = baseline; AET = adjuvant endocrine therapy, Rx = prescription
1The χ2 compared the portion of white, non-Latina participants to minority-identified participants
2The χ2 compared cancer stage categories of 0–I to II–III